Scholarlink

Introduction <p>Palmoplantar pustulosis (PPP) is a debilitating skin condition characterized by pustules, erythema, and scales on the palms and soles. Treatment adherence in psoriatic diseases is suboptimal.</p> Methods <p>A retrospective cohort study, using healthcare claims data from patients aged ≥ 18&#xa0;years with newly diagnosed PPP (selected between October 1, 2016 and March 31, 2020 from IBM<sup>®</sup> MarketScan<sup>®</sup> Commercial and the Optum<sup>®</sup> Clinformatics<sup>®</sup> Data Mart databases), was conducted to investigate adherence to and persistence with biologics in patients with PPP.</p> Results <p>Biologics were dispensed to 114/840 (13.6%) MarketScan and 76/750 (10.1%) Optum patients. Mean proportion of days covered (PDC; range) for biologics was similar between databases (MarketScan, 66% [8–100%]; Optum, 61% [8–99%]), and good adherence (≥ 80% PDC) was infrequent (MarketScan, 42.1%; Optum, 34.2%). Mean (standard deviation) persistence was slightly longer in MarketScan (283 [121] days) versus Optum (275 [133] days). Mean (range) adherence was similar between ages, although persistence was longer in patients aged 18–64 versus ≥ 65&#xa0;years (279 [132] vs 258 [140] days).</p> Conclusion <p>In patients with PPP, adherence to biologics was poor and persistence was variable; understanding and addressing the reasons behind these observations may improve treatment outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Biologic Treatment Adherence and Persistence in Patients with Palmoplantar Pustulosis: A Real-World, Claims-Based Study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月3日

查看全文
  • Steven R. Feldman,
  • Ran Gao,
  • Rhonda L. Bohn,
  • Stephani Gray,
  • Anouk Déruaz-Luyet,
  • Jashin J. Wu

摘要

Introduction

Palmoplantar pustulosis (PPP) is a debilitating skin condition characterized by pustules, erythema, and scales on the palms and soles. Treatment adherence in psoriatic diseases is suboptimal.

Methods

A retrospective cohort study, using healthcare claims data from patients aged ≥ 18 years with newly diagnosed PPP (selected between October 1, 2016 and March 31, 2020 from IBM® MarketScan® Commercial and the Optum® Clinformatics® Data Mart databases), was conducted to investigate adherence to and persistence with biologics in patients with PPP.

Results

Biologics were dispensed to 114/840 (13.6%) MarketScan and 76/750 (10.1%) Optum patients. Mean proportion of days covered (PDC; range) for biologics was similar between databases (MarketScan, 66% [8–100%]; Optum, 61% [8–99%]), and good adherence (≥ 80% PDC) was infrequent (MarketScan, 42.1%; Optum, 34.2%). Mean (standard deviation) persistence was slightly longer in MarketScan (283 [121] days) versus Optum (275 [133] days). Mean (range) adherence was similar between ages, although persistence was longer in patients aged 18–64 versus ≥ 65 years (279 [132] vs 258 [140] days).

Conclusion

In patients with PPP, adherence to biologics was poor and persistence was variable; understanding and addressing the reasons behind these observations may improve treatment outcomes.